Literature DB >> 20495622

Large-scale analysis of DNA methylation in chronic lymphocytic leukemia.

Farahnaz B Rahmatpanah1, Stephanie Carstens, Sam I Hooshmand, Elise C Welsh, Ozy Sjahputera, Kristen H Taylor, Lynda B Bennett, Huidong Shi, J Wade Davis, Gerald L Arthur, Tait D Shanafelt, Neil E Kay, James E Wooldridge, Charles W Caldwell.   

Abstract

AIMS: B-cell chronic lymphocytic leukemia (CLL) is a heterogeneous malignancy that clinically ranges from indolent to rapidly progressive. CLL, like other cancers, can be affected by epigenetic alterations. MATERIALS &
METHODS: A microarray discovery-based study was initiated to determine DNA methylation in CLL cases with a range of CD38 expression (1–92%).
RESULTS: Many loci were either methylated or unmethylated across all CD38 levels, but differential methylation was also observed for some genes. Genomic sequencing of DLEU7 confirmed extensive cytosine methylation preferentially in patient samples with low CD38 expression, whereas NRP2, SFRP2 and ADAM12 were more commonly methylated in those with high CD38 expression.
CONCLUSION: This study demonstrates that CLL is affected by CpG island methylation in some genes that segregate with CD38 expression levels, while most others show similar methylation patterns across all levels. The CpG island methylation in certain functional gene groups and pathway-associated genes that are known to be deregulated in CLL provides additional insights into the CLL methylome and epigenetic contribution to cellular dysfunction. It will now be useful to investigate the effectiveness of epigenetic therapeutic reversal of these alterations to develop effective treatments for the disease.

Entities:  

Keywords:  CD38 expression; CLL; DNA methylation; epigenetics; leukemia

Mesh:

Substances:

Year:  2009        PMID: 20495622      PMCID: PMC2872502          DOI: 10.2217/epi.09.10

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  53 in total

1.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

Authors:  Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  DAVID: Database for Annotation, Visualization, and Integrated Discovery.

Authors:  Glynn Dennis; Brad T Sherman; Douglas A Hosack; Jun Yang; Wei Gao; H Clifford Lane; Richard A Lempicki
Journal:  Genome Biol       Date:  2003-04-03       Impact factor: 13.583

3.  Simultaneous expression of CD38 and its ligand CD31 by chronic lymphocytic leukemia B-cells: anecdotal observation or pathogenetic hypothesis for the clinical outcome?

Authors:  Fortunato Morabito; Massimo Mangiola; Caterina Stelitano; Silvia Deaglio; Vincenzo Callea; Fabio Malavasi
Journal:  Haematologica       Date:  2003-03       Impact factor: 9.941

4.  V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.

Authors:  Alexander Kröber; Till Seiler; Axel Benner; Lars Bullinger; Elsbeth Brückle; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

5.  TCL1 is activated by chromosomal rearrangement or by hypomethylation.

Authors:  M R Yuille; A Condie; E M Stone; J Wilsher; P S Bradshaw; L Brooks; D Catovsky
Journal:  Genes Chromosomes Cancer       Date:  2001-04       Impact factor: 5.006

6.  Wnt signaling in B-cell neoplasia.

Authors:  Ya-Wei Qiang; Yoshimi Endo; Jeffrey S Rubin; Stuart Rudikoff
Journal:  Oncogene       Date:  2003-03-13       Impact factor: 9.867

7.  Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing.

Authors:  Kristen H Taylor; Robin S Kramer; J Wade Davis; Juyuan Guo; Deiter J Duff; Dong Xu; Charles W Caldwell; Huidong Shi
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 8.  Chronic lymphocytic leukemia: biology and current treatment.

Authors:  Clive S Zent; Neil E Kay
Journal:  Curr Oncol Rep       Date:  2007-09       Impact factor: 5.075

9.  Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression.

Authors:  A Sengupta; D Banerjee; S Chandra; S K Banerji; R Ghosh; R Roy; S Banerjee
Journal:  Leukemia       Date:  2007-03-15       Impact factor: 11.528

10.  Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia.

Authors:  Aparna Raval; Stephan M Tanner; John C Byrd; Elizabeth B Angerman; James D Perko; Shih-Shih Chen; Björn Hackanson; Michael R Grever; David M Lucas; Jennifer J Matkovic; Thomas S Lin; Thomas J Kipps; Fiona Murray; Dennis Weisenburger; Warren Sanger; Jane Lynch; Patrice Watson; Mary Jansen; Yuko Yoshinaga; Richard Rosenquist; Pieter J de Jong; Penny Coggill; Stephan Beck; Henry Lynch; Albert de la Chapelle; Christoph Plass
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

View more
  23 in total

1.  Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia.

Authors:  Lirong Pei; Jeong-Hyeon Choi; Jimei Liu; Eun-Joon Lee; Brian McCarthy; James M Wilson; Ethan Speir; Farrukh Awan; Hongseok Tae; Gerald Arthur; Jennifer L Schnabel; Kristen H Taylor; Xinguo Wang; Dong Xu; Han-Fei Ding; David H Munn; Charles Caldwell; Huidong Shi
Journal:  Epigenetics       Date:  2012-06-01       Impact factor: 4.528

2.  Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Enping Xu; Jian Gu; Ernest T Hawk; Kenneth K Wang; Maode Lai; Maosheng Huang; Jaffer Ajani; Xifeng Wu
Journal:  Carcinogenesis       Date:  2013-08-29       Impact factor: 4.944

3.  Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia.

Authors:  Lynda B Bennett; Kristen H Taylor; Gerald L Arthur; Farahnaz B Rahmatpanah; Sam I Hooshmand; Charles W Caldwell
Journal:  Epigenomics       Date:  2010-02-01       Impact factor: 4.778

Review 4.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

5.  BRCA2 promoter hypermethylation in sporadic breast cancer.

Authors:  Rémy Bosviel; Julie Durif; Jiaoli Guo; Mourad Mebrek; Fabrice Kwiatkowski; Yves-Jean Bignon; Dominique J Bernard-Gallon
Journal:  OMICS       Date:  2012-12

6.  Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia.

Authors:  Marta Kulis; Simon Heath; Marina Bibikova; Ana C Queirós; Alba Navarro; Guillem Clot; Alejandra Martínez-Trillos; Giancarlo Castellano; Isabelle Brun-Heath; Magda Pinyol; Sergio Barberán-Soler; Panagiotis Papasaikas; Pedro Jares; Sílvia Beà; Daniel Rico; Simone Ecker; Miriam Rubio; Romina Royo; Vincent Ho; Brandy Klotzle; Lluis Hernández; Laura Conde; Mónica López-Guerra; Dolors Colomer; Neus Villamor; Marta Aymerich; María Rozman; Mónica Bayes; Marta Gut; Josep L Gelpí; Modesto Orozco; Jian-Bing Fan; Víctor Quesada; Xose S Puente; David G Pisano; Alfonso Valencia; Armando López-Guillermo; Ivo Gut; Carlos López-Otín; Elías Campo; José I Martín-Subero
Journal:  Nat Genet       Date:  2012-10-14       Impact factor: 38.330

Review 7.  Uncovering the DNA methylome in chronic lymphocytic leukemia.

Authors:  Nicola Cahill; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-01-15       Impact factor: 4.528

8.  ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia.

Authors:  Silvia Martinelli; Meena Kanduri; Rossana Maffei; Stefania Fiorcari; Jenny Bulgarelli; Roberto Marasca; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-05-14       Impact factor: 4.528

Review 9.  Evolving understanding of the CLL genome.

Authors:  Michaela Gruber; Catherine J Wu
Journal:  Semin Hematol       Date:  2014-05-15       Impact factor: 3.851

Review 10.  Personalized medicine in CLL: current status and future perspectives.

Authors:  Uri Rozovski; Inbal Hazan-Halevy; Michael J Keating; Zeev Estrov
Journal:  Cancer Lett       Date:  2013-07-20       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.